查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1646787

全球單核細胞活化試驗 (MAT) 市場

Monocyte Activation Tests (MAT)
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 244 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球單核球活化試驗 (MAT) 市場規模將達到 2.855 億美元

2024 年全球單核細胞活化試驗 (MAT) 市場規模估計為 9,470 萬美元，預計到 2030 年將達到 2.855 億美元，2024-2030 年分析期內的複合年成長率為 20.2%。 MAT套件是報告中分析的細分市場之一，預計到分析期結束時複合年成長率為 18.5%，達到 1.572 億美元。在分析期內，MAT 試劑部分的成長率預計將達到 22.5% 的複合年成長率。

美國市場規模估計為 2,520 萬美元，中國市場預計複合年成長率為 19.0%

預計到 2024 年美國核細胞活化測試 (MAT) 市場價值將達到 2,520 萬美元。中國是世界第二大經濟體，預計到 2030 年市場規模將達到 4,340 億美元，2024 年至 2030 年的複合年成長率為 19.0%。其他值得注意的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為 18.3% 和 17.5%。在歐洲，德國的複合年成長率預計為 15.0%。

全球單核細胞活化測試市場 - 主要趨勢與促進因素摘要

什麼是單核細胞活化試驗 (MAT)？

單核細胞活化試驗 (MAT) 是一種檢測藥品、醫療設備和生物製藥中是否存在熱原的體外檢測方法。這些測試利用人類單核細胞或單核細胞系，在暴露於熱原時釋放促炎細胞激素，如 IL-6 和 TNF-α。 MAT 是傳統兔熱原試驗 (RPT ) 和鱟變形細胞裂解物 (LAL) 測試的可靠替代方案，可確保注射藥物、疫苗、靜脈注射液和植入式醫療設備。

單核細胞活化測試的重要性在於其準確性、與人類的相關性以及檢測內毒素和非內毒素熱原的能力。與僅檢測內毒素的 LAL 檢測不同，MAT 可以識別更廣泛的熱原，確保對藥物和醫療設備進行全面的安全評估。 MAT 符合 3R （替代、減少、改進）原則，旨在盡量減少在測試中使用動物。這使得 MAT 不僅能有效檢測熱原，而且在道德上符合安全測試方面的最新監管要求和行業標準。

技術進步如何影響單核細胞活化測試市場？

技術進步顯著提高了單核細胞活化測試的效率、靈敏度和可重複性，促進了藥物安全測試的創新。一項重大進展是使用冷凍保存的人類單核細胞，這提高了 MAT 的一致性和可用性。冷凍保存的細胞提供了標準化、即用型測試解決方案，減少了結果的差異性並提高了不同實驗室的可重複性。這些進步使得 MAT 更容易取得，特別是在新血供應有限或不切實際的環境中。

自動化 MAT 平台的發展使得熱原測試更具擴充性和效率。自動化系統簡化了從樣品準備到資料分析的整個測試過程，減少了人工錯誤並提高了吞吐量。自動化使 MAT 更適合生物製藥製造中的大規模篩檢，因為該領域需要進行大量測試以確保產品安全。此外，使用高通量篩檢(HTS)技術可以快速識別熱原，支援在藥物開發和批量發布期間進行快速安全評估。

細胞激素檢測和即時PCR等分析技術的進步提高了 MAT 的靈敏度和準確性。這些技術可以同時測量多種細胞激素，從而提供更全面的熱原活性概況。與先進的資料分析和人工智慧 (AI) 工具的整合進一步改善了對 MAT 結果的解釋，從而能夠在產品安全評估中做出更快、更準確的決策。這些創新不僅擴展了單核細胞活化測試的能力，而且符合藥物安全測試的自動化、提高靈敏度和道德測試的更廣泛趨勢。

單核細胞活化試驗在各領域有哪些新的應用？

由於生物製藥、醫療設備和疫苗對可靠、道德和全面的熱原檢測的需求，單核細胞活化測試在各個領域的應用越來越廣泛。在生物製藥領域，MAT 廣泛用於測試注射藥物，包括單株抗體、重組蛋白以及細胞和基因療法等生技藥品。 MAT 檢測內毒素和非內毒素熱原的能力對於確保這些複雜生物製藥的安全至關重要，而傳統的 LAL 測試可能會遺漏某些污染物。

在疫苗產業，MAT 在確保疫苗安全方面發揮關鍵作用，尤其是採用 mRNA 和病毒載體等現代方法開發的疫苗。鑑於快速開發和大規模生產的需求，MAT 提供了一種可靠的、非動物源的替代方案，可納入疫苗品管流程。 MAT 特別適用於檢測新疫苗製劑中的熱原，例如在 COVID-19 大流行期間開發的疫苗製劑，其中快速、合乎道德和準確的測試至關重要。

在醫療設備產業，MAT 用於檢測植入裝置、透析液和輸液中的熱原污染物。由於醫療設備經常與體液直接接觸，因此必須進行嚴格的熱原測試，以防止產生不良的免疫反應。 MAT 對這些醫療設備提供了更全面的安全評估，支援法規遵循並提高病患安全。在化妝品領域，MAT 用於評估注射化妝品（如真皮填充劑）的安全性，以確保它們不含有害的熱原。

在研發領域，MAT 在藥物和產品開發的早期階段的應用越來越多。在臨床前試驗中使用 MAT 可讓研究人員在開發過程的早期識別和消除致熱風險，從而提高獲得監管部門核准的機會並降低後期失敗的成本。 MAT 在這些領域的應用不斷擴大，凸顯了其在提高安全性、支持倫理試驗以及簡化藥品、醫療設備及相關產品的品管方面發揮的重要作用。

是什麼推動了單核細胞活化測試市場的成長？

單核細胞活化測試 (MAT) 市場的成長受到多種因素的推動，例如對全面熱原測試的需求不斷增加、對道德測試方法的採用日益增多以及生物製藥開發的進步。主要成長要素之一是向非動物測試方法的轉變。隨著 FDA 和 EMA 等監管機構推動採用符合 3R 原則的體外方法，MAT 正逐漸成為一種有效的替代動物熱原測試方法，例如兔熱原測試 (RPT)。監管部門對倫理測試的推動正在加速 MAT 在製藥和醫療設備製造領域的應用。

生物製藥和先進療法的日益複雜性進一步推動了對 MAT 的需求。生技藥品、生物相似藥、細胞和基因療法以及 mRNA 疫苗的興起推動了對能夠檢測一系列熱原的安全測試的需求。 MAT 能夠識別內毒素和非內毒素熱原，因此成為傳統內毒素檢測可能不足的先進療法的首選。

自動化、高通量篩檢和冷凍保存細胞技術的進步也促進了 MAT 市場的成長。自動化和高通量能力使 MAT 更具可擴展性和高效性，支援其在大規模生物製藥生產和批量放行測試中的使用。冷凍保存單核細胞的使用使得 MAT 更加可靠、更少變化，並且更易於在不同實驗室中常規使用。

製藥和醫療設備業嚴格的安全法規和品質控制標準進一步推動了 MAT 的採用。全面的熱原檢測的監管要求使得製造商必須實施嚴格的安全測試通訊協定。 MAT 不僅符合這些監管要求，還提供了一種更快速、更可靠、更符合道德的熱原檢測方法，使其成為現代安全評估策略的關鍵組成部分。

由於細胞化驗分析技術的不斷創新、體外測試的監管支援以及生物製藥的日益複雜性，MAT 市場有望實現強勁成長。這些趨勢，加上對可靠、全面和道德的熱原檢測的日益成長的需求，使得 MAT 成為廣泛領域的藥品品管、生物製藥開發和法規遵循的重要組成部分。

部分

產品類型（MAT套件、MAT 試劑）、來源（基於周邊血單核細胞 (PBMC)、基於細胞株）、最終用途（製藥最終用途、生物技術最終用途、醫療設備最終用途、其他最終用途）

受訪企業範例（共41家）

  • Becton, Dickinson & Company
  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Microcoat Biotechnologie GmbH
  • Sanquin
  • Solvias AG
  • Thermo Fisher Scientific, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP16601

Global Monocyte Activation Tests (MAT) Market to Reach US$285.5 Million by 2030

The global market for Monocyte Activation Tests (MAT) estimated at US$94.7 Million in the year 2024, is expected to reach US$285.5 Million by 2030, growing at a CAGR of 20.2% over the analysis period 2024-2030. MAT Kits, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$157.2 Million by the end of the analysis period. Growth in the MAT Reagents segment is estimated at 22.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.2 Million While China is Forecast to Grow at 19.0% CAGR

The Monocyte Activation Tests (MAT) market in the U.S. is estimated at US$25.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$43.4 Million by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.3% and 17.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global Monocyte Activation Tests Market - Key Trends & Drivers Summarized

What Are Monocyte Activation Tests (MAT), and Why Are They So Crucial in Modern Biopharmaceutical Safety?

Monocyte Activation Tests (MAT) are in-vitro assays that detect the presence of pyrogens—fever-inducing substances, in pharmaceutical products, medical devices, and biologicals. These tests utilize human monocytes or monocytic cell lines, which, upon exposure to pyrogens, release pro-inflammatory cytokines like IL-6 and TNF-α. MAT offers a reliable alternative to traditional rabbit pyrogen tests (RPT) and Limulus Amebocyte Lysate (LAL) tests, making it a critical tool in ensuring the safety and quality of injectable drugs, vaccines, intravenous solutions, and implantable medical devices.

The importance of monocyte activation tests lies in their accuracy, human relevance, and ability to detect both endotoxins and non-endotoxin pyrogens. Unlike LAL tests, which only detect endotoxins, MAT can identify a broader spectrum of pyrogens, ensuring comprehensive safety assessments for pharmaceuticals and medical devices. MAT is aligned with the principles of the 3Rs (Replacement, Reduction, Refinement), which aim to minimize the use of animals in testing. This makes MAT not only effective in detecting pyrogens but also ethically aligned with modern regulatory requirements and industry standards in safety testing.

How Are Technological Advancements Shaping the Monocyte Activation Tests Market?

Technological advancements have significantly enhanced the efficiency, sensitivity, and reproducibility of Monocyte Activation Tests, driving innovation in pharmaceutical safety testing. One of the major developments is the use of cryopreserved human monocytes, which have improved the consistency and availability of MAT. Cryopreserved cells provide standardized and ready-to-use testing solutions, reducing variability in test results and improving reproducibility across different laboratories. This advancement has made MAT more accessible, especially in settings where fresh blood supply is limited or impractical.

The development of automated MAT platforms has further improved the scalability and efficiency of pyrogen testing. Automated systems streamline the entire testing process, from sample preparation to data analysis, reducing manual errors and enhancing throughput. Automation has made MAT more suitable for large-scale screening in biopharmaceutical manufacturing, where high-volume testing is required to ensure product safety. Additionally, the use of high-throughput screening (HTS) technologies has enabled faster identification of pyrogens, supporting rapid safety assessments during drug development and batch release.

Advancements in analytical techniques, such as multiplex cytokine assays and real-time PCR, have increased the sensitivity and accuracy of MAT. These techniques allow for the simultaneous measurement of multiple cytokines, providing a more comprehensive profile of pyrogenic activity. Integration with advanced data analytics and artificial intelligence (AI) tools has further improved the interpretation of MAT results, enabling faster and more precise decision-making in product safety evaluations. These technological innovations not only expand the capabilities of monocyte activation tests but also align with broader trends toward automation, higher sensitivity, and ethical testing in pharmaceutical safety.

What Are the Emerging Applications of Monocyte Activation Tests Across Different Sectors?

Monocyte Activation Tests are finding expanding applications across various sectors, driven by the need for reliable, ethical, and comprehensive pyrogen detection in biopharmaceuticals, medical devices, and vaccines. In the biopharmaceutical sector, MAT is widely used for testing injectable drugs, including biologics like monoclonal antibodies, recombinant proteins, and cell or gene therapies. The ability of MAT to detect both endotoxin and non-endotoxin pyrogens is critical for ensuring the safety of these complex biological products, where traditional LAL tests may miss certain contaminants.

In the vaccine industry, MAT plays a vital role in ensuring the safety of vaccines, particularly those developed through modern methods like mRNA or viral vectors. Given the need for rapid development and mass production, MAT offers a reliable, non-animal-based alternative that can be integrated into vaccine quality control pipelines. It is particularly valuable in detecting pyrogens in new vaccine formulations, such as those developed during the COVID-19 pandemic, where rapid, ethical, and accurate testing was essential.

In the medical device industry, MAT is used to test implantable devices, dialysis fluids, and intravenous solutions for pyrogenic contaminants. Since medical devices often come into direct contact with body fluids, rigorous pyrogen testing is necessary to prevent adverse immune reactions. MAT provides a more comprehensive safety assessment for these devices, supporting regulatory compliance and improving patient safety. In the cosmetic sector, MAT is used to evaluate the safety of injectable cosmetic products like dermal fillers, ensuring they are free from harmful pyrogens.

In research and development, MAT is increasingly employed during the early stages of drug and product development. Its use in preclinical testing allows researchers to identify and eliminate pyrogenic risks early in the development process, improving the likelihood of regulatory approval and reducing costs associated with late-stage failures. The expanding applications of MAT across these sectors highlight its critical role in enhancing safety, supporting ethical testing, and improving efficiency in the quality control of pharmaceuticals, medical devices, and related products.

What Drives Growth in the Monocyte Activation Tests Market?

The growth in the Monocyte Activation Tests (MAT) market is driven by several factors, including increasing demand for comprehensive pyrogen testing, rising adoption of ethical testing methods, and advancements in biopharmaceutical development. One of the primary growth drivers is the shift toward non-animal testing methods. As regulatory agencies like the FDA and EMA promote the adoption of in-vitro methods aligned with the 3Rs principles, MAT has gained traction as an effective alternative to animal-based pyrogen tests like the rabbit pyrogen test (RPT). This regulatory push toward ethical testing has accelerated the adoption of MAT in pharmaceutical and medical device manufacturing.

The growing complexity of biopharmaceuticals and advanced therapies has further fueled demand for MAT. With the rise of biologics, biosimilars, cell and gene therapies, and mRNA vaccines, there is a greater need for safety tests that can detect a wide range of pyrogens. MAT’s ability to identify both endotoxin and non-endotoxin pyrogens makes it a preferred choice for these advanced therapies, where traditional endotoxin tests may be insufficient.

Advancements in automation, high-throughput screening, and cryopreserved cell technology have also contributed to the growth of the MAT market. Automation and high-throughput capabilities have made MAT more scalable and efficient, supporting its use in large-scale biopharmaceutical production and batch release testing. The availability of cryopreserved monocytes has improved MAT’s reliability, reducing variability and making it more practical for routine use across different testing sites.

Stringent safety regulations and quality control standards in the pharmaceutical and medical device industries have further driven the adoption of MAT. Regulatory requirements for comprehensive pyrogen testing have made it essential for manufacturers to implement robust safety testing protocols. MAT not only meets these regulatory requirements but also offers a faster, more reliable, and ethical approach to pyrogen detection, making it a key component of modern safety assessment strategies.

With ongoing innovations in cell-based assays, regulatory support for in-vitro testing, and the growing complexity of biopharmaceutical products, the MAT market is poised for robust growth. These trends, combined with increasing demand for reliable, comprehensive, and ethical pyrogen detection, make MAT a vital component of pharmaceutical quality control, biopharmaceutical development, and regulatory compliance across various sectors.

SCOPE OF STUDY:

The report analyzes the Monocyte Activation Tests (MAT) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (MAT Kits, MAT Reagents); Source (Peripheral Blood Mononuclear Cell (PBMC) Based, Cell Line Based); End-Use (Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Becton, Dickinson & Company
  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Microcoat Biotechnologie GmbH
  • Sanquin
  • Solvias AG
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Monocyte Activation Tests - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Need for Pyrogen Testing Drives Demand for Monocyte Activation Tests
    • Increasing Focus on Patient Safety in Drug Development Sets the Stage for Market Growth
    • Strong Regulatory Support for Safer Drug Testing Strengthens Business Case
    • Growing Use in Biopharmaceutical Production Expands Addressable Market
    • Growing Role in Quality Control Generates Demand in Pharmaceutical Industry
    • Increasing Focus on Animal-free Testing Drives Adoption of Monocyte Activation Tests
    • Expanding Use in Vaccine Safety Testing Sets the Stage for Market Expansion
    • Rising Focus on Endotoxin-free Manufacturing Generates Demand
    • Use in Cell Therapy Development Propels Monocyte Activation Test Market
    • Increasing Applications in Oncology and Immunotherapy Strengthen Market Position
    • Growing Role in Risk Assessment for Blood Products Drives Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Monocyte Activation Tests (MAT) Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Monocyte Activation Tests (MAT) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for MAT Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for MAT Kits by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for MAT Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for MAT Reagents by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Peripheral Blood Mononuclear Cell (PBMC) Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Peripheral Blood Mononuclear Cell (PBMC) Based by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cell Line Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Cell Line Based by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharmaceutical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharmaceutical End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biotechnology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Biotechnology End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Medical Device End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Medical Device End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION